Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) FCF Margin (2022 - 2026)

TriSalus Life Sciences has reported FCF Margin over the past 5 years, most recently at 74.4% for Q1 2026.

  • For Q1 2026, FCF Margin fell 1710.0% year-over-year to 74.4%; the TTM value through Mar 2026 reached 43.33%, up 6735.0%, while the annual FY2025 figure was 40.04%, 9990.0% up from the prior year.
  • FCF Margin for Q1 2026 was 74.4% at TriSalus Life Sciences, down from 18.85% in the prior quarter.
  • Over five years, FCF Margin peaked at 18.85% in Q4 2025 and troughed at 583.23% in Q3 2022.
  • A 5-year average of 186.73% and a median of 166.91% in 2023 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 27297bps in 2024 and later plummeted -1710bps in 2026.
  • Year by year, FCF Margin stood at 263.92% in 2022, then surged by 37bps to 166.91% in 2023, then soared by 56bps to 73.26% in 2024, then skyrocketed by 74bps to 18.85% in 2025, then tumbled by -295bps to 74.4% in 2026.
  • Business Quant data shows FCF Margin for TLSI at 74.4% in Q1 2026, 18.85% in Q4 2025, and 32.44% in Q3 2025.